Resultados de la búsqueda 1471-1480 of 16312 for Epilepsy (Partial Onset)

1. Efectos secundarios del Neurontin: claves para controlarlos - Mayo Clinic

   Epilepsy Foundation. https://www.epilepsy.com/tools-resources/seizure-medication-list/gabapentin. Accessed May 21, 20205. Neurontin (prescribing information) ...

2. Convulsiones febriles - Síntomas y causas - Mayo Clinic

   AskMayoExpert. Febrile seizure (child). Mayo Clinic. 2019. Subcommittee on Febrile Seizures. Febrile seizures: Guideline for the neurodiagnostic evaluation of ...

3. Neurología - Ensayos clínicos

   ... focal epilepsy of unknown cause (high) compared to patients with epilepsy of known cause (intermediate) and idiopathic genetic generallized epilepsy (low).

4. Ensayos clínicos - Neurología

   Study Of Neurophysiologically Based Brain State Tracking And Modulation In Focal Epilepsy. Rochester, Minn. The purpose of this study is to track seizure ...

5. Neurología - Ensayos clínicos - Mayo Clinic

   A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

6. Neurología - Ensayos clínicos

   ... focal epilepsy of unknown cause (high) compared to patients with epilepsy of known cause (intermediate) and idiopathic genetic generallized epilepsy (low).

7. Neurología - Ensayos clínicos - Mayo Clinic

   A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

8. Neurología - Ensayos clínicos - Mayo Clinic

   A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

9. Hematología - Ensayos clínicos - Mayo Clinic

   ... onset of therapy. A Study Of ABBV-383 With Relapsed Refractory Waldenström Macroglobulinemia. Rochester, Minn. The purpose of this study is to determine the ...

10. Neurología - Ensayos clínicos

    ... focal epilepsy of unknown cause (high) compared to patients with epilepsy of known cause (intermediate) and idiopathic genetic generallized epilepsy (low).